Table 2.

Factors predictive for progression‐free survival and overall survival among patients with carcinomas of unknown primary who received systemic therapy (N = 62). CI, confidence interval; HR, hazard ratio.

Characteristics	Progression‐free survival				Overall survival
	Univariate		Multivariate a		Univariate		Multivariate a
	Median, months	P‐value	HR (95%CI)	P‐value	Median, months	P‐value	HR (95%CI)	P‐value
Age, years b
≥ 64 [N = 30] vs. < 64 [N = 32]	3.8 vs. 2.8	0.09	0.81 (0.43–1.52)	0.51	6.9 vs. 10.8	0.89	—	—
Sex
Female [N = 35] vs. male [N = 27]	4.0 vs. 2.7	0.47	—	—	6.9 vs. 11.9	0.35	—	—
Histology
Adenocarcinoma [N = 32] vs. not [N = 30]	4.0 vs. 2.5	0.53	—	—	7.7 vs. 10.8	0.65	—	—
Treatment
Administered as 1st line [N = 41] vs. ≥ 2nd line [N = 21]	3.1 vs. 3.7	0.80	—	—	7.7 vs. 11.7	0.63	—	—
≥ 2 drugs [N = 50] vs. single drug [N = 21]	3.1 vs. 3.8	0.95	—	—	10.8 vs. 20.7	0.60	—	—
Matched [N = 37] vs. Unmatched [N = 25]	3.7 vs. 3.8	0.41	—	—	13.4 vs. 6.9	0.31	—	—
Matching Score > 50% [N = 15] vs. ≤ 50% [N = 47] c	10.4 vs. 2.8	0.002	0.23 (0.07–0.74)	0.014	15.8 vs. 6.9	0.09	—	—
Immunotherapy based [N = 18] vs. other [N = 44] d	6.2 vs. 3.7	0.063	1.32 (0.54–3.22)	0.54	15.8 vs. 7.6	0.30	—	—

^a Variables with P‐values < 0.1 in the univariate analysis were included for multivariate analysis. Multivariate analysis was not performed for the overall survival since Matching Score was the only variable with P < 0.1.

^b Age at treatment initiation. Dichotomized by the median value.

^c Low Matching Score group includes 25 patients with Matching Score = 0 (unmatched) and 22 patients with Matching Score of 1 to 50%.

^d N = 44 patients received non‐immunotherapy‐based therapies.